Comparative Pharmacology
Head-to-head clinical analysis: DERMA SMOOTHE FS versus PREDNICARBATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DERMA SMOOTHE FS versus PREDNICARBATE.
DERMA-SMOOTHE/FS vs PREDNICARBATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluocinolone acetonide is a corticosteroid that binds to glucocorticoid receptors, modulating gene transcription to inhibit pro-inflammatory cytokines and reduce inflammation, vasodilation, and edema.
Prednicarbate is a corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. It binds to glucocorticoid receptors, leading to inhibition of phospholipase A2, decreased release of arachidonic acid, and reduced synthesis of prostaglandins and leukotrienes.
Apply topically as a thin film to affected areas twice daily. Maximum weekly dose should not exceed 60 g.
Topical: apply sparingly to affected area twice daily; maximum 50 g per week.
None Documented
None Documented
Clinical Note
moderatePrednicarbate + Gatifloxacin
"The risk or severity of adverse effects can be increased when Prednicarbate is combined with Gatifloxacin."
Clinical Note
moderatePrednicarbate + Rosoxacin
"The risk or severity of adverse effects can be increased when Prednicarbate is combined with Rosoxacin."
Clinical Note
moderatePrednicarbate + Levofloxacin
"The risk or severity of adverse effects can be increased when Prednicarbate is combined with Levofloxacin."
Clinical Note
moderateTerminal elimination half-life: 24-36 hours (systemic absorption after topical application); clinical context: prolonged with hepatic impairment.
Terminal elimination half-life: approximately 1-2 hours; clinical context: short half-life supports topical use with minimal systemic accumulation
Primarily renal (90%) as inactive metabolites; <5% unchanged. Biliary/fecal excretion accounts for <10%.
Primarily renal (<2% unchanged) and fecal (biliary excretion of metabolites)
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid
Prednicarbate + Trovafloxacin
"The risk or severity of adverse effects can be increased when Prednicarbate is combined with Trovafloxacin."